Literature DB >> 12677301

Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities.

Wouter A P Breeman1, Marion De Jong, Theo J Visser, Jack L Erion, Eric P Krenning.   

Abstract

DOTA-conjugated peptides, such as [DOTA(0),Tyr(3)]octreotide (DOTATOC) and [DOTA(0),Tyr(3)]octreotate (DOTA-tate), can be labelled with radionuclides such as (90)Y, (111)In and (177)Lu. These radiolabelled somatostatin analogues are used for peptide receptor radionuclide therapy (PRRT). Radioligands for PRRT require high specific activities. However, although these radionuclides are produced without addition of carrier, contaminants are introduced during production and as decay products. In this study, parameters influencing the kinetics of labelling of DOTA-peptides were investigated and conditions were optimised to obtain the highest achievable specific activity. The effects of contaminants were systematically investigated, concentration dependently, in a test model mimicking conditions for labelling with minimal molar excess of DOTA-peptides over radionuclide. Kinetics of labelling of DOTA-peptides were optimal at pH 4-4.5; pH <4 strongly slowed down the kinetics. Above pH 5, reaction kinetics varied owing to the formation of radionuclide hydroxides. Labelling with (90)Y and (177)Lu was completed after 20 min at 80 degrees C, while labelling with (111)In was completed after 30 min at 100 degrees C. The effects of contaminants were systematically categorised, e.g. Cd(2+) is the target and decay product of (111)In, and it was found to be a strong competitor with (111)In for incorporation in DOTA. In contrast, Zr(4+) and Hf(4+), decay products of (90)Y and (177)Lu, respectively, did not interfere with the incorporation of these radionuclides. The following conclusions are drawn: (a) DOTA-peptides can be radiolabelled at high specific activity; (b) reaction kinetics differ for each radionuclide; and (c) reactions can be hampered by contaminants, such as target material and decay products.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12677301     DOI: 10.1007/s00259-003-1142-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  12 in total

Review 1.  G-protein coupled receptor kinases as modulators of G-protein signalling.

Authors:  M Bünemann; M M Hosey
Journal:  J Physiol       Date:  1999-05-15       Impact factor: 5.182

2.  (90)Y and (177)Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy.

Authors:  S Liu; E Cheung; M C Ziegler; M Rajopadhye; D S Edwards
Journal:  Bioconjug Chem       Date:  2001 Jul-Aug       Impact factor: 4.774

Review 3.  Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.

Authors:  W A Breeman; M de Jong; D J Kwekkeboom; R Valkema; W H Bakker; P P Kooij; T J Visser; E P Krenning
Journal:  Eur J Nucl Med       Date:  2001-09

4.  In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man.

Authors:  W H Bakker; E P Krenning; W A Breeman; P P Kooij; J C Reubi; J W Koper; M de Jong; J S Laméris; T J Visser; S W Lamberts
Journal:  J Nucl Med       Date:  1991-06       Impact factor: 10.057

5.  Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.

Authors:  D L Kukis; S J DeNardo; G L DeNardo; R T O'Donnell; C F Meares
Journal:  J Nucl Med       Date:  1998-12       Impact factor: 10.057

6.  DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy.

Authors:  A Otte; E Jermann; M Behe; M Goetze; H C Bucher; H W Roser; A Heppeler; J Mueller-Brand; H R Maecke
Journal:  Eur J Nucl Med       Date:  1997-07

7.  The chemistry of gallium and indium as related to radiopharmaceutical production.

Authors:  S M Moerlein; M J Welch
Journal:  Int J Nucl Med Biol       Date:  1981

8.  [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients.

Authors:  D J Kwekkeboom; W H Bakker; P P Kooij; M W Konijnenberg; A Srinivasan; J L Erion; M A Schmidt; J L Bugaj; M de Jong; E P Krenning
Journal:  Eur J Nucl Med       Date:  2001-09

Review 9.  Peptide receptor imaging and therapy.

Authors:  D Kwekkeboom; E P Krenning; M de Jong
Journal:  J Nucl Med       Date:  2000-10       Impact factor: 10.057

10.  Synthesis and characterisation of [90Y]-Bz-DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours.

Authors:  P M Smith-Jones; B Stolz; R Albert; G Ruser; U Briner; H R Mäcke; C Bruns
Journal:  Nucl Med Biol       Date:  1998-04       Impact factor: 2.408

View more
  47 in total

1.  Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT).

Authors:  Nicoletta Urbano; Stefano Papi; Mauro Ginanneschi; Rita De Santis; Silvia Pace; Ragnar Lindstedt; Liliana Ferrari; Sunju Choi; Giovanni Paganelli; Marco Chinol
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-06       Impact factor: 9.236

2.  Radiolabelling DOTA-peptides with 68Ga.

Authors:  Wouter A P Breeman; Marion de Jong; Erik de Blois; Bert F Bernard; Mark Konijnenberg; Eric P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-01-18       Impact factor: 9.236

3.  Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging.

Authors:  William M Rockey; Ling Huang; Kyle C Kloepping; Nicholas J Baumhover; Paloma H Giangrande; Michael K Schultz
Journal:  Bioorg Med Chem       Date:  2011-05-14       Impact factor: 3.641

Review 4.  Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.

Authors:  Ashutosh Dash; Maroor Raghavan Ambikalmajan Pillai; Furn F Knapp
Journal:  Nucl Med Mol Imaging       Date:  2015-02-17

Review 5.  Radiopharmaceutical development of radiolabelled peptides.

Authors:  Melpomeni Fani; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

6.  Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis.

Authors:  Amir Sabet; Feras Khalaf; Torjan Haslerud; Abdullah Al-Zreiqat; Amin Sabet; Birgit Simon; Thorsten D Pöppel; Hans-Jürgen Biersack; Samer Ezziddin
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-09-19

7.  153Sm and 166Ho complexes with tetraaza macrocycles containing pyridine and methylcarboxylate or methylphosphonate pendant arms.

Authors:  Fernanda Marques; Krassimira P Guerra; Lurdes Gano; Judite Costa; M Paula Campello; Luís M P Lima; Rita Delgado; Isabel Santos
Journal:  J Biol Inorg Chem       Date:  2004-08-28       Impact factor: 3.358

8.  A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues.

Authors:  Rogier P J Schroeder; Cristina Müller; Suzanne Reneman; Marleen L Melis; Wout A P Breeman; Erik de Blois; Chris H Bangma; Eric P Krenning; Wytske M van Weerden; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-25       Impact factor: 9.236

9.  Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours.

Authors:  Marleen Melis; Magda Bijster; Monique de Visser; Mark W Konijnenberg; Jan de Swart; Edgar J Rolleman; Otto C Boerman; Eric P Krenning; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12       Impact factor: 9.236

10.  Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma.

Authors:  Alida C Fröberg; Marion de Jong; Berthold A Nock; Wout A P Breeman; Jack L Erion; Theodosia Maina; Marion Verdijsseldonck; Wouter W de Herder; Aad van der Lugt; Peter P M Kooij; Eric P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-06       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.